Biotech Acquisition Common Stock

Biotech Acquisition's common stock stands at $230M as of September 2022. That compares with $230M in the prior-year period — up 0.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Biotech Acquisition reported $230M in common stock versus $230M a year earlier — a 0.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $230M in the prior-year period — up 0.6% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Biotech Acquisition's common stock evolved across reporting periods, while the comparison chart places BIOT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.